KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q3 2025 value amounting to -$31.6 million.

  • Ginkgo Bioworks Holdings' Free Cash Flow rose 7334.85% to -$31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$187.2 million, marking a year-over-year increase of 5166.37%. This contributed to the annual value of -$382.1 million for FY2024, which is 1362.62% down from last year.
  • As of Q3 2025, Ginkgo Bioworks Holdings' Free Cash Flow stood at -$31.6 million, which was up 7334.85% from -$40.3 million recorded in Q2 2025.
  • In the past 5 years, Ginkgo Bioworks Holdings' Free Cash Flow registered a high of -$10.7 million during Q3 2021, and its lowest value of -$170.7 million during Q4 2021.
  • Over the past 5 years, Ginkgo Bioworks Holdings' median Free Cash Flow value was -$70.1 million (recorded in 2021), while the average stood at -$77.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 36863.45% in 2023, then surged by 7334.85% in 2025.
  • Ginkgo Bioworks Holdings' Free Cash Flow (Quarter) stood at -$170.7 million in 2021, then rose by 23.72% to -$130.2 million in 2022, then skyrocketed by 52.93% to -$61.3 million in 2023, then rose by 8.38% to -$56.1 million in 2024, then soared by 43.71% to -$31.6 million in 2025.
  • Its Free Cash Flow was -$31.6 million in Q3 2025, compared to -$40.3 million in Q2 2025 and -$59.1 million in Q1 2025.